Iovance Biotherapeutics Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial
Reuters
Nov 03, 2025
<a href="https://laohu8.com/S/IOVA">Iovance Biotherapeutics</a> Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial
Iovance Biotherapeutics Inc. has announced interim results from its registrational Phase 2 IOV-LUN-202 trial evaluating lifileucel, a tumor infiltrating lymphocyte $(TIL)$ cell therapy, as a monotherapy in patients with previously treated advanced nonsquamous non-small cell lung cancer (NSCLC) without actionable genetic mutations. The interim data showed a 26% objective response rate, with the median duration of response not reached after 25 months of follow-up. The safety profile for lifileucel was consistent with expectations, and improvements were observed following an updated regimen of reduced non-myeloablative lymphodepletion. Additional data from the IOV-LUN-202 trial will be presented at a medical meeting in 2026. Iovance anticipates submitting a supplemental Biologics License Application in 2026 and a potential launch for lifileucel in this indication in the second half of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566984-en) on November 03, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.